Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
核心洞察
A secondary analysis of the IMPROVE trial found that the digital Integrative Medicine@Home (IM@Home) program was associated with improved overall survival in patients with solid tumors undergoing systemic therapy.
At a median follow-up of 28.6 months, median overall survival was not reached in the IM@Home group versus 26.3 months in the control group, with 24-month survival rates of 69.1% versus 52.6% (P = .037).
In adjusted analyses accounting for tumor type and stage, IM@Home was associated with a lower risk of death (hazard ratio = 0.59), though the finding did not remain statistically significant in sensitivity analyses.
A digitally delivered integrative medicine program may improve not only symptom burden but also overall survival in patients undergoing systemic cancer (搜索) treatment, according to a secondary analysis of the IMPROVE trial conducted by the Integrative Medicine and Wellness Service at Memorial Sloan Kettering Cancer Center (MSKCC).
The Integrative Medicine for Patient-Reported Outcomes, Values, and Experience (IMPROVE) trial was developed in response to the challenges posed by the COVID-19 pandemic. Researchers evaluated whether a 12-week multimodality digital integrative medicine program, Integrative Medicine@Home (IM@Home), incorporating evidence-based mind-body therapies such as yoga and mindfulness along with structured exercise, could improve symptom burden and quality of life. A total of 200 patients with solid tumors receiving systemic therapy or radiation and experiencing moderate to severe fatigue (搜索) were randomly assigned to IM@Home or an enhanced usual care control group that received access to on-demand meditation resources in addition to usual care.
The IM@Home intervention was delivered remotely through multiple weekly class offerings using a scalable digital model that enabled patients to access care from home while addressing common barriers such as geographic distance, cost, and scheduling constraints. The original trial results showed that IM@Home significantly reduced fatigue (搜索), anxiety, depression, and overall symptom burden compared with enhanced usual care, while also reducing emergency department visits, hospitalizations, and treatment disruptions.
Secondary Survival Analysis
In this follow-up study, investigators explored whether the improvements in symptoms and well-being observed in the IMPROVE trial translated into better long-term clinical outcomes, particularly overall survival. The secondary analysis included 127 of the original 200 participants with solid tumors who experienced fatigue (搜索) during systemic therapy.
Results showed a clinically meaningful improvement in overall survival among patients assigned to the IM@Home intervention. At a median follow-up of 28.6 months, median overall survival was not reached in the IM@Home group, compared with 26.3 months in the control group. At 24 months, the estimated overall survival rate was 69.1% in the IM@Home group versus 52.6% in the control group (P = .037). In adjusted analyses accounting for tumor type and stage, IM@Home was associated with a lower risk of death (hazard ratio = 0.59), although the finding did not remain statistically significant in sensitivity analyses.
According to the investigators, these findings suggest that a relatively brief, nonpharmacologic integrative medicine intervention may have meaningful downstream effects on survival.
Context Within Integrative Oncology
These findings are particularly notable in the broader context of integrative oncology. Current clinical guidelines, including those from ASCO and the Society for Integrative Oncology, recommend mind-body therapies and exercise for symptom management in patients with cancer (搜索). However, evidence linking these interventions to improved survival has been limited. This secondary analysis provides preliminary evidence that such interventions may also influence longer-term clinical outcomes.
"The observed improvement in overall survival suggests that addressing symptom burden through a structured integrative medicine program during active treatment may have broader clinical impact," the study authors noted.
The authors highlighted several potential mechanisms that could explain the observed survival benefit, including reductions in fatigue (搜索) and stress, as well as better adherence to cancer (搜索) treatment. Improvements in symptom burden may enable patients to better tolerate and complete treatment, potentially contributing to improved long-term clinical outcomes.
"By targeting multiple domains simultaneously, the IM@Home intervention reflects a whole-person approach that may influence both psychological and physiological pathways relevant to cancer (搜索) outcomes," the study authors noted.
Study Limitations
The authors emphasized that these findings should be interpreted with caution. The survival analysis was exploratory, and the trial was not originally powered to detect differences in overall survival. As with many behavioral interventions, unmeasured confounding factors, such as differences in participant engagement or motivation, may also have influenced the results. Despite these limitations, the findings are hypothesis-generating and provide a strong rationale for future trials specifically designed to evaluate survival outcomes.
Implications for Practice and Research
This study contributes to the growing body of evidence supporting integrative oncology. The findings reinforce the importance of addressing symptom burden as a core component of comprehensive cancer (搜索) care, particularly given the established association between symptoms such as fatigue (搜索) and poorer clinical outcomes. They also provide preliminary evidence that patient-centered, multicomponent interventions delivered in a fully digital format may have effects beyond symptom management and could influence longer-term clinical outcomes.
The intervention's digital delivery model offers a scalable approach to expanding access to supportive care services, particularly for patients who face logistical barriers to in-person care. Another notable aspect of the study is its emphasis on patient-centered care. The intervention was designed to address patient-reported symptoms and experiences, aligning with a growing emphasis in oncology on prioritizing the patient experience alongside traditional clinical endpoints. The inclusion of multiple modalities also allows for individualized participation, which may enhance engagement and effectiveness.
The secondary survival analysis of the IMPROVE trial provides promising evidence that a digitally delivered integrative oncology program may improve not only symptom burden but also overall survival in patients undergoing systemic cancer (搜索) treatment. Although additional research is needed to confirm these findings and clarify the underlying mechanisms, the study highlights the potential for integrative, patient-centered, and accessible interventions to play a broader role in cancer care. If confirmed in larger trials, these findings could support the broader integration of multimodal, nonpharmacologic interventions into standard oncology care.